ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study

Journal of B.U.ON.

Volumn 15, Issue 4, 2010, Pages 794-796

  Turhal, N Serdar ^a   Bas, E ^a   Er, O ^b   Aliustaoglu, M ^c   Seber, S ^a   Dane, F ^a   Korkmaz, T ^a   Soyuer, I ^d   Ozkara, S ^c   Celikel, C ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Acibadem Maslak Hospital   (Turkey)

^c GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^d ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

ERCC1; Hepatocellular cancer; Immunohistochemistry

Indexed keywords

BIOTIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PEROXIDASE; STREPTAVIDIN;

ADULT; ARTICLE; CANCER PATIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STANDARD; TREATMENT RESPONSE;

CARCINOMA, HEPATOCELLULAR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 78651403902     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl 1): S20-S37.
2. Addeo R, Caraglia M, Del Prete S. Highlights of the Regional Meeting of the Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guidelines and perspectives. Expert Opin Investig Drugs 2009; 18: 373-378.
3. http://ukdk.org/. Web site of National Cancer Advisory Board of Turkey.
4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
5. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002; 38: 217-227.
6. Soria J, Haddad V, Olaussen KA et al. Immunohistochemical staining of the Excision Repair Cross-Complementing 1 (ERCC1) protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT). ASCO Ann Meet Proceed Part I. J Clin Oncol 2006; 24 (Suppl): 7010 (abstr).
7. Joshi MB, Shirota Y, Danenberg KD et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11: 2215-2221.
8. Falkson G, Ryan LM, Johnson LA et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987; 60: 2141-2145.
9. Vander Borght S, Komuta M, Libbrecht L et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008; 28: 1370-1380.
10. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 2000; 21: 1527-1530.
11. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002; 94: 393-397. (Pubitemid 34081368)
12. Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 2008; 18: 702-710.